Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30729563 | 1.00 | PPM1D (0.34) | PPM1DNR1H2 | |
| SCHEMBL29245844 | 1.00 | PPM1D (0.34) | PPM1DNR1H2 | |
| SCHEMBL376587 | 1.00 | PPM1D (0.34) | PPM1DNR1H2 | |
| SCHEMBL5314317 | 1.00 | PPM1D (0.34) | PPM1DNR1H2 | |
| SCHEMBL2634064 | 1.00 | PPM1D (0.34) | PPM1DNR1H2 | |
| SCHEMBL3470472 | 1.00 | PPM1D (0.34) | PPM1DNR1H2 | |
| SCHEMBL924412 | 0.87 | PPM1D (0.34) | PPM1D | |
| SCHEMBL4725652 | 0.87 | BDKRB2 (0.34) | PPM1D | |
| SCHEMBL28580288 | 0.87 | PPM1D (0.34) | PPM1D | |
| SCHEMBL4416435 | 0.86 | PPM1D (0.33) | PPM1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240165244-A1 | BRM Targeting Compounds And Associated Methods Of Use | PRELUDE THERAPEUTICS INCORPORATED | 2024-05-23 | — | — | US | disclosed |
| US-7659279-B2 | 2-{(2S)-2-[({4-[3-Chloro-4-fluoroanilino]-7-methoxyquinazolin-5-yl}oxy)methyl]pyrrolidin-1-yl}-2-oxoethanol; epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors; breast, colorectal and head and neck cancer | ASTRAZENECA AB (SE) | 2010-02-09 | — | — | US | disclosed |
| US-20090264431-A1 | NOVEL CATHEPSIN C INHIBITORS AND THEIR USE | GLAXO GROUP LIMITED (GB) | 2009-10-22 | — | — | US | disclosed |
| EP-1622620-B1 | QUINAZOLINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2008-02-20 | — | — | EP | disclosed |
| US-20060211714-A1 | Quinazoline derivatives and their use in the treatment of cancer | ASTRAZENECA AB (SE) | 2006-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264431-A1 | NOVEL CATHEPSIN C INHIBITORS AND THEIR USE | CTSB, CTSS, CTSF | PPM1D 4382/4885NR1H2 1784/4885 |
| US-20240165244-A1 | BRM Targeting Compounds And Associated Methods Of Use | ABCG2, BRIX1, MRPS28 | PPM1D 4208/4885NR1H2 276/4885 |
| US-20060211714-A1 | Quinazoline derivatives and their use in the treatment of cancer | EGFR, ERBB2, ERBB4 | PPM1D 675/4885NR1H2 1756/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.